The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease
Open accessAbstract
OBJECTIVE: To determine the frequency and correlates of impulse control disorders (ICDs) in Parkinson disease (PD). DESIGN: An unstructured screening interview for ICDs (compulsive gambling, buying, and sexual behavior) followed by a telephone-administered structured interview for screen-positive patients. SETTING: Two university-affiliated movement disorders centers. PARTICIPANTS: A convenience sample of 272 patients with idiopathic PD who were screened for psychiatric complications. MAIN OUTCOME MEASURES: Presence of compulsive gambling, buying, or sexual behavior as assessed by the Minnesota Impulsive Disorders Interview. RESULTS: Eighteen patients (6.6%) with PD met criteria for an ICD at some point during the course of PD, including 11 (4.0%) with an active ICD. Compulsive gambling and compulsive sexual behavior were equally common. In a multivariate model, treatment with a dopamine agonist (P = .01) and a history of ICD symptoms prior to PD onset (P = .02) predicted current ICD. There were no differences between the dopamine agonists in their association with ICDs (P = .21), and daily doses of dopamine agonists were higher in patients with an ICD than in dopamine agonist-treated patients without an ICD (P < .001). CONCLUSIONS: Patients with PD treated with a dopamine agonist should be made aware of the risk of developing an ICD and monitored clinically. Because dopamine agonists are increasingly being used for other indications, future research should assess the dopamine agonist-associated risk for ICDs in other populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“impulse-control disorder (ICD) development in PD patients has been associated with dopamine agonist pharmacotherapy (Weintraub et al., 2006”
From Remote delivery of psychological interventions for Parkinson's disease. (2018) · cites this paper as Weintraub et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
An algorithm (decision tree) for the management of Parkinson’s disease (2001):
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 724
Compulsive buying: descriptive characteristics and psychiatric comorbidity.
Ga, C., Faber, R., de Zwaan, M., Raymond, N. C., Sm, S., Ekern, Tb, M., Crosby, R. D., Sj, C., & Ed, E. (1994) · PubMed · Cited by 664
Giovannoni, G. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.4.423 · Cited by 587
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Dodd, M. L., Klos, K. J., Bower, J. H., Geda, Y. E., Josephs, K. A., & Ahlskog, J. E. (2005) · Archives of Neurology · doi:10.1001/archneur.62.9.noc50009 · Cited by 563
Flagged first, then by citations
Research works printed but not linked: 2
- [4]American Psychiatric Association. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000. Diagnostic and Statistical Manual of Mental Disorders. [Google Scholar]
- [6]Tyne HL, Medley G, Ghadiali E, Steigner MJ. Gambling in Parkinson’s disease. Movement Disorders. 2004;19(suppl 9):S195. [Google Scholar]
Cited by
Sorted by citations
Items 201–300 of 661
van Wouwe, N. C., Pallavaram, S., Phibbs, F. T., Martínez-Ramírez, D., Neimat, J. S., Dawant, B. M., D’Haese, P.-F., Kanoff, K. E., van den Wildenberg, W. P. M., Okun, M. S., et al. (2017) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2017.02.016 · Cited by 47
Neuropsychiatric symptoms in untreated Parkinson’s disease
Szatmári, S., Illigens, B. M. W., Siepmann, T., Pintér, A., Takáts, A., & Bereczki, D. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s130997 · Cited by 47
“108 The association between high doses of dopaminergic medications, particularly dopamine agonists and increased risk to develop ICDs, seems evident; 20,109,110 however, currently available literature deals with PD patients undergoing DRT only.”
BackgroundSchapira, A. H. V., Hartmann, A., & Agid, Y. (2009) · Wiley eBooks · doi:10.1002/9781444306385.ch3 · Cited by 47
Clinical aspects of impulsive compulsive behaviours in Parkinson's disease
Djamshidian, A., Averbeck, B. B., Lees, A. J., & O’Sullivan, S. S. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.07.031 · Cited by 46
“No difference in the frequency of ICB has been reported between pramipexole and ropinirole [6,8,10].”
BackgroundInfluentialThe treatment of erectile dysfunction in patients with neurogenic disease.
Shridharani, A., & Brant, W. O. (2016) · PubMed Central · doi:10.3978/j.issn.2223-4683.2016.01.07 · Cited by 46
“Dopaminergic therapy for PD can improve ED, and sometimes therapy may lead to hypersexuality (43,44).”
BackgroundTranslational Models of Gambling-Related Decision-Making
Winstanley, C. A., & Clark, L. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5014 · Cited by 50
Dopamine-Induced Nonmotor Symptoms of Parkinson's Disease
Park, A., & Stacy, M. A. (2011) · Parkinson s Disease · doi:10.4061/2011/485063 · Cited by 47
“One study found that only 25% of PD patients with an active ICD were identified clinically [9].”
BackgroundNew developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease
Goetz, C. G. (2010) · Movement Disorders · doi:10.1002/mds.22636 · Cited by 45
Sleep and impulsivity in Parkinson's disease
Scullin, M. K., Sollinger, A. B., Land, J. O., Wood‐Siverio, C., Zanders, L., Lee, R., Freeman, A., Goldstein, F. C., Bliwise, D. L., & Factor, S. A. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.06.018 · Cited by 45
“Impulsivity is linked more to dopamine agonists than levodopa [6], and may or may not be related to dosage [5,8].”
Tremblay, M., Silveira, M. M., Kaur, S., Hosking, J. G., Adams, W. K., Baunez, C., & Winstanley, C. A. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13332 · Cited by 46
“Such DRT-ICDs result in significant psychosocial distress and serious impairments in quality of life that can even surpass the disability caused by PD (Weintraub & Potenza, 2006; Weintraub et al., 2006, 2010; Voon et al., 2011b).”
BackgroundAdvances in dopamine receptor agonists for the treatment of Parkinson’s disease
Stocchi, F., Torti, M., & FOSSATI, C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1219337 · Cited by 45
Reward processing abnormalities in Parkinson's disease
Kapogiannis, D., Mooshagian, E., Campion, P., Grafman, J. H., Zimmermann, T. J., Ladt, K. C., & Wassermann, E. M. (2011) · Movement Disorders · doi:10.1002/mds.23701 · Cited by 48
Hicks, C. W., Pandya, M., Itin, I., & Fernandez, H. H. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.03.003 · Cited by 43
“2% in the presence of any dopamine agonist [1], and compulsive sexual behavior may be as equally common [2].”
BackgroundHeiden, P., Heinz, A., & Romanczuk‐Seiferth, N. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13396 · Cited by 43
“dopamine replacement therapy, specifically with dopamine agonists (Voon et al., 2006; Weintraub et al., 2006; Gallagher et al., 2007).”
BackgroundInfluentialUpdate on the use of pramipexole in the treatment of Parkinson’s disease
Constantinescu, R. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2325 · Cited by 43
“Weintraub et al investigated the prevalence of ICD in 272 PD patients, half of which were treated with a DA (pramipexole, ropinirole, pergolide) (Weintraub et al 2006).”
A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease
Ceravolo, R., Rossi, C., Del Prete, E., & Bonuccelli, U. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1130128 · Cited by 44
Diagnosis and treatment of impulse control disorders in patients with movement disorders
Mestre, T., Strafella, A. P., Thomsen, T. R., Voon, V., & Miyasaki, J. M. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613476127 · Cited by 41
“Initial studies of ICDs in PD [Pontone et al. 2006; Weintraub et al. 2006; Grosset et al. 2011; Isaias et al. 2008; Singh et al. 2007; Voon et al. 2006] reported a prevalence of 2.”
BackgroundInfluentialOlanow, C. W., Kieburtz, K. D., Leinonen, M., Elmer, L. W., Giladi, N., Hauser, R. A., Klepiskaya, O. S., Kreitzman, D. L., Lew, M., Russell, D., et al. (2017) · Movement Disorders · doi:10.1002/mds.26941 · Cited by 41
“Many of these side effects occur with increased frequency with higher doses.(8,9) Monoamine oxidase-B (MAO-B) inhibitors, such as rasagiline, have also been recommended as an initial therapy for PD(1) because of their potential to provide symptomatic effects with a good adverse event profile and potential diseasemodif…”
BackgroundSexual Disorders and Quality of Life in Parkinson's Disease
Malcher, C. M. S. R., de Oliveira, K. R. D. S. G., Caldato, M. C. F., Santos‐Lobato, B. L., Pedroso, J. D. S., & Scanavino, M. D. T. (2021) · Sexual Medicine · doi:10.1016/j.esxm.2020.10.008 · Cited by 44
“3%.(66,110,111) Using levodopa alone, the risk is 2.”
BackgroundTanaka, K., Wada‐Isoe, K., Nakashita, S., Yamamoto, M., & Nakashima, K. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.05.013 · Cited by 41
“⁎ χ test revealed that treatment with dopamine agonists is associated with the development of ICBs in PD patients [22,23,24,25].”
BackgroundImpulsive and compulsive behaviors in Parkinson's disease: A one-year follow-up study
Ávila, A., Cardona, X., Martín‐Baranera, M., Bello, J., & Sastre, F. F. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.05.044 · Cited by 40
Management of psychiatric disorders in Parkinson's disease
Weintraub, D. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00875-w · Cited by 42
Self-citationGenetic prediction of impulse control disorders in Parkinson's disease
Weintraub, D. A., Posavi, M., Fontanillas, P., Tropea, T. F., Mamikonyan, E., Suh, E. R., Trojanowski, J. Q., Cannon, P., Deerlin, V. M. V., & Chen‐Plotkin, A. S. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51569 · Cited by 40
“reports, corroborated by our current study, suggest that a large proportion of PD individuals may suffer from ICD during their disease course.(2,4,5,14,31) These impulsive behaviors are strongly associated with the use of DAs.”
BackgroundResultSelf-citationImpact of Mood and Behavioral Disorders on Quality of Life in Parkinson’s disease
Rieu, I., Houeto, J. L., Pereira, B., de Chazeron, I., Bichon, A., Chéreau, I., Ulla, M., Brefel‐Courbon, C., Ory‐Magne, F., Dujardin, K., et al. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-150747 · Cited by 39
“More recently, Impulse Control and Repetitive Behavior Disorders (ICRBs) have been described [12–14].”
Adams, W. K., Haar, C. V., Tremblay, M., Cocker, P. J., Silveira, M. M., Kaur, S., Baunez, C., & Winstanley, C. A. (2017) · eNeuro · doi:10.1523/eneuro.0094-17.2017 · Cited by 45
“…of serious impulse control and addiction problems, including gambling disorder (GD), has made neurologists reluctant to prescribe this class of drugs, despite their noted efficacy at restoring motor function (Lawrence et al., 2003; Evans and Lees, 2004; Weintraub et al., 2006; Voon et al., 2011).”
BackgroundFaure, A., Leblanc-Veyrac, P., & Massioui, N. E. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.03.047 · Cited by 40
Munhoz, R. P., Fabiani, G., Becker, N., & Teive, H. A. G. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00861.x · Cited by 39
Hinojosa‐Amaya, J. M., Johnson, N., Gonzalez‐Torres, C., Varlamov, E. V., Yedinak, C. G., McCartney, S., & Fleseriu, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.579606 · Cited by 40
“In addition to the well-known side effects, such as nausea, dizziness, orthostatic hypotension, and headaches (7), which are usually preventable with slow up-titration in most clinical scenarios (15) some psychiatric side effects, such as ICD, have been noted (10, 19, 20).”
BackgroundAdverse Events from the Treatment of Parkinson's Disease
Chou, K. L. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.05.003 · Cited by 37
Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients
Burdick, K. E., Braga, R. J., Gopin, C. B., & Malhotra, A. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.177 · Cited by 37
“…disorders in individuals with no prior history of such difficulties (Dodd et al, 2005; DriverDunckley et al, 2007; Giovannoni et al, 2000; Klos et al, 2005; Madden et al, 2010; McKeon et al, 2007; Munhoz et al, 2009; Potenza et al, 2007; Riba et al, 2008; Voon et al, 2006b; Weintraub et al, 2006).”
BackgroundResultEffects of pramipexole on impulsive choice in male wistar rats.
Madden, G. J., Johnson, P. S., Brewer, A. T., Pinkston, J. W., & Fowler, S. C. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0019244 · Cited by 37
“Other cases of DA agonistrelated problem behavior have involved compulsive shopping and hypersexuality (Dodd et al., 2005; Driver-Dunckley et al., 2007; Giladi, Weitzman, Schreiber, Shabtai, & Peretz, 2007; Giovannoni, O’Sullivan, Turner, Manson, & Lees, 2000; Klos, Bower, Josephs, Matsumoto, & Ahlskog, 2005; McKeon e…”
Impulse control disorders in Parkinson’s disease
Marquès, A., Durif, F., & Fernagut, P. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1870-8 · Cited by 37
Impulsive and Compulsive Behaviors in Parkinson’s Disease
Zhang, G., Zhang, Z., Liu, L., Yang, J., Huang, J., Xiong, N., & Wang, T. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00318 · Cited by 40
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
Zhang, J., & Tan, L. C. S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208114634 · Cited by 36
“Since then, many reports have found ICDs such as pathological gambling [7375], compulsive buying [76], hypersexuality [73, 76], and impulsive smoking [77] to be associated with the use of DA.”
BackgroundRole of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease
Cools, R., Tichelaar, J. G., Helmich, R. C. G., Bloem, B. R., Esselink, R. A. J., Smulders, K., & Timmer, M. H. M. (2022) · Progress in brain research · doi:10.1016/bs.pbr.2022.01.012 · Cited by 38
“…side effects as a consequence of this medication in the form of impulse control disorder (ICD), or even of psychosis and addiction (Dagher and Robbins, 2009; Driver-Dunckley et al., 2003; Lawrence et al., 2003; Pontone et al., 2006; Voon and Fox, 2007; Voon et al., 2017; Weintraub et al., 2006).”
Labudda, K., Brand, M., Mertens, M., Ollech, I., Markowitsch, H. J., & Woermann, F. G. (2010) · Behavioural Neurology · doi:10.1155/2010/743141 · Cited by 36
Cognitive and Personality Features in Parkinson Disease: 2 Sides of the Same Coin?
Volpato, C., Signorini, M., Meneghello, F., & Semenza, C. (2009) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0b013e3181c12c63 · Cited by 37
Martínez‐Martín, P., Payo, B. F., Agüera-Ortíz, L., & Ayuga-Martinez, A. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6490-x · Cited by 36
“These data agree with previous estimations of prevalence for psychotic disorders (50 %) [18, 52] and for punding (14 %) [53] pathologic gambling, shopping, and other abnormal behaviors (14 %) [54, 55] which may be simultaneously present in the same patient (4 %) [10, 54, 56, 57].”
ResultClinical characteristics of impulse control and repetitive behavior disorders in Parkinson’s disease
Kim, J., Kim, M., Kwon, D., Seo, W., Kim, J. H., Baik, J. S., & Koh, S. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6645-9 · Cited by 35
“Although no statistical distinction was seen between non-ICRB and a single ICRB, or between a single ICRB and two ICRBs, significant distinctions were seen between the 0- and 2-ICRB groups.”
BackgroundInfluentialDepression and Psychosis in Neurological Practice
Murray, E. D., & Price, B. H. (2008) · Elsevier eBooks · doi:10.1016/b978-0-7506-7525-3.50011-x · Cited by 35
The Role of Sex Therapy in the Management of Patients with Parkinson's Disease
Bronner, G., & Korczyn, A. D. (2017) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12561 · Cited by 35
“Dopaminergic treatment, particularly dopamine agonists, may induce behavioral addictions termed impulse-control disorders, including hypersexuality.(46,47) This compulsive SPB imposes distress and anger on partners, family, and staff members.”
BackgroundRuitenberg, M. F. L., Wu, T., Averbeck, B. B., Chou, K. L., Koppelmans, V., & Seidler, R. D. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00279 · Cited by 36
“As medication dosage affects impulsivity (6), this may explain the discrepancy in behavioral results on the beads task.”
Neurobiologia dos transtornos do controle dos impulsos
Williams, W. A., & Potenza, M. N. (2008) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462008005000003 · Cited by 37
“These findings suggest that confounding factors (for example, prescribing patterns related to DA agonist selection and dosage) may have contributed to earlier reports.(29) From a biological perspect ive, these f indings suggest that speculations regarding the involvement of specific dopamine receptor subtypes, for exa…”
BackgroundResultSelf-citationCognitive impulsivity in Parkinson's disease patients: Assessment and pathophysiology
Robert, G., Drapier, D., Vérin, M., Millet, B., Azulay, J., & Blin, O. (2009) · Movement Disorders · doi:10.1002/mds.22836 · Cited by 38
“Sub-Thalamic Nucleus-Deep Brain Stimulation (STN-DBS) is used successfully to manage motor symptoms in PD.”
BackgroundInfluentialNeural and behavioral substrates of subtypes of Parkinson’s disease
Moustafa, A. A., & Poletti, M. (2013) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2013.00117 · Cited by 35
Ramirez‐Zamora, A., Gee, L. E., Boyd, J. T., & Biller, J. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1158103 · Cited by 34
Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson’s Disease
Carvalho, M. M., Campos, F. L., Marques, M., Soares‐Cunha, C., Kokras, N., Dalla, C., Leite‐Almeida, H., Sousa, N., & Salgado, A. J. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00145 · Cited by 39
“In the clinical context of human PD, the use of DAg has been more strongly linked to the development of ICD than LD (Driver-Dunckley et al., 2003; Weintraub et al., 2006).”
BackgroundLauring, J. O., Ishizu, T., Kutlikova, H. H., Dörflinger, F., Haugbøl, S., Leder, H., Kupers, R. C., & Pelowski, M. J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.12.016 · Cited by 35
Impulse control disorders in Parkinson's disease: A 20‐year odyssey
Weintraub, D. A. (2019) · Movement Disorders · doi:10.1002/mds.27668 · Cited by 34
“Early cross-sectional studies generated initial point prevalence rates for most ICDs in PD as well as examining the suspected link with PD medication use.(6,7) However, it took a motivated pharmaceutical company to fund the pivotal and definitive cross-sectional DOMINION study in which an ICD was identified in 14% of…”
BackgroundSelf-citationAre there ethnic differences in impulsive/compulsive behaviors in Parkinson’s disease?
Chiang, H., Huang, Y., Chen, S. ‐., & Wu, Y. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03571.x · Cited by 34
“7% [25,28] and 2–8% in the general population in the US [36]; however, no patient was found to have CS in our study or in Fan et al.”
BackgroundImpulse Control Disorders Arising in 3 Patients Treated With Rotigotine
Wingo, T. S., Evatt, M. L., Scott, B. L., Freeman, A., & Stacy, M. A. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181684542 · Cited by 34
“6%.(11) Thus, levodopa therapy alone and in combination with dopamine agonist therapy have been temporally linked with new-onset hypersexuality(6,7,12,13); in addition, Uitti et al(13) also reported it occurring after thalamotomy.”
BackgroundAdvances in the genetics of Parkinson's disease
Rosner, S., Giladi, N., & Orr‐Urtreger, A. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00731.x · Cited by 35
Reward pathways in Parkinson's disease: Clinical and theoretical implications
Torta, D. M. E., & Castelli, L. (2008) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2008.01756.x · Cited by 36
Lee, S., Kim, D. J., Svenkeson, D., Parras, G. A., Oishi, M., & McKeown, M. J. (2015) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2015.00005 · Cited by 33
Long-Term Efficacy of Rasagiline in Early Parkinson's Disease
Lew, M., Hauser, R. A., Hurtig, H. I., Ondo, W. G., Wojcieszek, J., Goren, T., & Fitzer‐Attas, C. J. (2010) · International Journal of Neuroscience · doi:10.3109/00207451003778744 · Cited by 33
“They can cause daytime sleepiness, hallucinations, edema, and impulse control disorders (Aminoff, 2006; Happe & Berger, 2001; Miyasaki et al., 2002; Nirenberg & Waters 2006; O’Sullivan, Evans & Lees, 2009; Schapira & Obeso, 2006; Voon et al., 2006; Weintraub et al., 2006) Despite the potential risk of complications, t…”
BackgroundSáez‐Francàs, N., Martí‐Andrés, G., Ramírez, N. D., de Fàbregues, O., Álvarez-Sabín, J., Casas, M., & Hernández‐Vara, J. (2016) · Neurología (English Edition) · doi:10.1016/j.nrleng.2015.05.008 · Cited by 36
Ray, N. J., & Strafella, A. P. (2010) · Clinical EEG and Neuroscience · doi:10.1177/155005941004100208 · Cited by 34
Auyeung, M., Tsoi, T. H., Tang, W. K., Cheung, C. M., Lee, C. N., Li, R., & Yeung, E. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.06.001 · Cited by 33
“The use of a dopamine agonist (DA) to treat PD patients is associated with the occurrence of ICD [2].”
BackgroundResultMack, J., Okai, D., Brown, R. G., Askey‐Jones, S., Chaudhuri, К. R., Martin, A., Samuel, M., & David, A. S. (2013) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12030076 · Cited by 34
Elmer, L. W. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.06.001 · Cited by 33
Dysfunctional inhibitory control in Parkinson’s disease patients with levodopa-induced dyskinesias
Picazio, S., Ponzo, V., Caltagirone, C., Brusa, L., & Koch, G. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8945-1 · Cited by 33
Florin, E., Müller, D., Pfeifer, J., Barbe, M. T., Fink, G. R., & Timmermann, L. (2013) · Brain · doi:10.1093/brain/awt241 · Cited by 32
“agonists are linked to a higher impulsivity (Weintraub et al., 2006; Bódi et al., 2009).”
BackgroundCOMT and ANKK1 Genetics Interact With Depression to Influence Behavior Following Severe TBI
Myrga, J. M., Juengst, S. B., Failla, M. D., Conley, Y. P., Arenth, P. M., Grace, A. A., & Wagner, A. K. (2016) · Neurorehabilitation and neural repair · doi:10.1177/1545968316648409 · Cited by 33
Subthalamic Neural Activity Patterns Anticipate Economic Risk Decisions in Gambling
Mazzoni, A., Rosa, M., Carpaneto, J., Romito, L. M., Priori, A., & Micera, S. (2018) · eNeuro · doi:10.1523/eneuro.0366-17.2017 · Cited by 33
Psychotic and compulsive symptoms in Parkinson's disease
Verbaan, D., van Rooden, S. M., Jeukens‐Visser, M., Marinus, J., Emre, M., & van Hilten, J. J. (2009) · Movement Disorders · doi:10.1002/mds.22453 · Cited by 31
Impulse control disorders in Parkinson’s disease: clinical characteristics and implications
Leeman, R. F., & Potenza, M. N. (2011) · Neuropsychiatry · doi:10.2217/npy.11.11 · Cited by 34
Self-citationLongitudinal decline of driving safety in Parkinson disease
Uc, E. Y., Rizzo, M., O’Shea, A. M. J., Anderson, S. W., & Dawson, J. D. (2017) · Neurology · doi:10.1212/wnl.0000000000004629 · Cited by 31
Impulse control disorders in Parkinson disease: A cross-sectional study in Morocco
Otmani, H. E., Mouni, F. Z., Abdulhakeem, Z., Attar, Z., Rashad, L., Saali, I., Moutawakil, B. E., Rafai, M. A., Slassi, I., & Nadifi, S. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2018.07.009 · Cited by 30
Addictive behaviors and Parkinson's disease
Witjas, T., Eusébio, A., Fluchère, F., & Azulay, J. (2012) · Revue Neurologique · doi:10.1016/j.neurol.2012.06.014 · Cited by 30
Ceravolo, R., Frosini, D., Rossi, C., & Bonuccelli, U. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5715-0 · Cited by 41
“In the second study [25], 272 patients with PD at two movement disorder centres were screened for the presence”
BackgroundMethodInfluentialLawrence, A. D., & Brooks, D. J. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00086 · Cited by 32
“, Myers, J., and Kendler, K. S. (2012). Gambling, disordered gambling and their association with major depression and substance use: a web-”
BackgroundNoradrenergic contributions to cue-driven risk-taking and impulsivity
Chernoff, C. S., Hynes, T. J., & Winstanley, C. A. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05806-x · Cited by 32
Possible Sites of Therapeutic Action in Restless Legs Syndrome: Focus on Dopamine and α2δ Ligands
Thorpe, A. J., Clair, A. G., Hochman, S., & Clemens, S. (2011) · European Neurology · doi:10.1159/000328431 · Cited by 29
Compulsive buying in bipolar disorder: Is it a comorbidity or a complication?
Kesebir, S., İşitmez, S., & Gündoğar, D. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.09.037 · Cited by 29
“Dopaminergic mesolimbic stimulation activating a pathological process in the reward systems is suggested in the etiology (Grant et al., 2006; Weintraub et al., 2006).”
BackgroundRogers, R. D., wielenberg, B., Wojtecki, L., Elben, S., Campbell-Meiklejohn, D. K., & Schnitzler, A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.06.007 · Cited by 30
“…is associated with patterns of behavioural addictions, such as impulse control disorders (ICDs) and the ‘dopamine dysregulation syndrome’ (Ferrara and Stacy, 2008), in a minority of patients with Parkinson's Disease (PD) (Dagher and Robbins, 2009; Lim et al., 2009; Weintraub et al., 2006).”
BackgroundInfluentialDepression and Psychosis in Neurological Practice
Murray, E. D., Buttner, E. A., & Price, B. H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00009-8 · Cited by 29
Compulsive Behaviors in Patients With Parkinson's Disease
Kenangıl, G., Özekmekçi, S., Sohtaoğlu, M., & Erginöz, E. (2010) · The Neurologist · doi:10.1097/nrl.0b013e31819f952b · Cited by 29
Sexual function and depressive symptoms in young women with hypoprolactinaemia
Krysiak, R. G., Kowalcze, K. E., & Okopień, B. (2020) · Clinical Endocrinology · doi:10.1111/cen.14283 · Cited by 28
“55 (n [%]) At baseline 4 (27)*# 3 (12) 3 (10) After 6 mo 1 (7)& 2 (8) 3 (10)”
Buelow, M. T., Frakey, L. L., Grace, J., & Friedman, J. H. (2013) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/act065 · Cited by 28
“Risky decision-making is one area of executive functioning that has gained recent research interest in PD, likely due to reports of increased impulse control disorders and risk-taking behavior in PD and the use of dopamine agonist medications (Dodd et al., 2005; Weintraub et al., 2006, 2010).”
BackgroundImpulse Control Disorders and Co-Occurring Disorders: Dual Diagnosis Considerations
Potenza, M. N. (2007) · Journal of Dual Diagnosis · doi:10.1300/j374v03n02_06 · Cited by 28
Self-citationManagement of impulse control disorders in Parkinson’s disease
Galpern, W. R., & Stacy, M. A. (2007) · Current Treatment Options in Neurology · doi:10.1007/bf02938408 · Cited by 28
Influence of conditioned reinforcement on the response-maintaining effects of quinpirole in rats
Collins, G. T., & Woods, J. H. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e328330ad9b · Cited by 27
“…of reports have linked the use of D2-like agonists, in the treatment of Parkinson’s disease or restless-leg syndrome, with the development of compulsive patterns of goal-directed behaviors, such as gambling, shopping, eating, and hypersexuality (e.g. Weintraub et al., 2006; Voon and Fox, 2007).”
BackgroundDrug-Induced Impulse Control Disorders: A Prospectus for Neuroethical Analysis
Carter, A., Ambermoon, P., & Hall, W. (2010) · Neuroethics · doi:10.1007/s12152-010-9071-7 · Cited by 27
“ICDs reported after DRT treatment include: pathological gambling [19], compulsive buying [20, 21], hypersexuality [22], intermittent explosive disorder (IED) [23], internet or computer addiction [24], and compulsive eating [25].”
BackgroundSafarinejad, M. R., Taghva, A., Shekarchi, B., & Safarinejad, S. (2010) · International Journal of Impotence Research · doi:10.1038/ijir.2010.23 · Cited by 27
RetractedMridula, K. R., Borgohain, R., Jabeen, S. A., Gaddamanugu, P., Bandaru, V. S., Ankathi, P., Kanikannan, M. A., & Khan, M. S. A. (2015) · PubMed Central · Cited by 26
Sáez‐Francàs, N., Andrés, G. M., Ramírez, N. D., de Fàbregues, O., Álvarez‐Sabín, J., Casas, M., & Hernández‐Vara, J. (2015) · Neurología · doi:10.1016/j.nrl.2015.05.002 · Cited by 30
Cooper, C. A. (2009) · International Journal of General Medicine · doi:10.2147/ijgm.s4674 · Cited by 26
“Treatment with dopamine agonist therapy and a history of impulse control disorders has also been proposed as possible risk factors.(3) This study investigates prevalence and demographic characteristics of hypersexual behavior in PD patients residing in north central Florida, USA.”
Intertemporal choice in Parkinson's disease and restless legs syndrome
Al‐Khaled, M., Heldmann, M., Bolstorff, I., Hagenah, J. M., & Münte, T. F. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.026 · Cited by 25
Kon, T., Ueno, T., Haga, R., & Tomiyama, M. (2018) · Brain and Behavior · doi:10.1002/brb3.1036 · Cited by 25
Lee, J., Jeon, B., Koh, S., Yoon, W. T., Lee, H., Kwon, O. D., Kim, J. W., Kim, J., Ma, H., Kim, H.-T., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318942 · Cited by 25
Behavioral and Neuroanatomical Account of Impulsivity in Parkinson's Disease
Hlavatá, P., Linhartová, P., Šumec, R., Filip, P., Světlák, M., Baláž, M., Kašpárek, T., & Bareš, M. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2019.01338 · Cited by 29
The role of dopamine in action control: Insights from medication effects in Parkinson’s disease
Ruitenberg, M. F. L., van Wouwe, N. C., Wylie, S. A., & Abrahamse, E. L. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.04.023 · Cited by 25
Boutros, S. W., Raber, J., & Unni, V. K. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212566 · Cited by 28
Impulsive smoking in a patient with Parkinson’s disease treated with dopamine agonists
Bienfait, K., Menza, M. A., Mark, M. H., & Dobkin, R. D. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.09.001 · Cited by 25
Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists
Kostić, V. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70839-9 · Cited by 25
“[55] suggested that reports of younger PD”
The Iowa Gambling Task and the three fallacies of dopamine in gambling disorder
Linnet, J. (2013) · Frontiers in Psychology · doi:10.3389/fpsyg.2013.00709 · Cited by 27
“Parkinson’s disease sufferers, who are treated with dopamine agonists, have significantly higher prevalence of gambling disorder than individuals who receive other forms of treatment (Grosset et al., 2006; Lu et al., 2006; Weintraub et al., 2006).”
BackgroundRuiz, P. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01041 · Cited by 25
“It was also clear that ICDwas associated with antiparkinsonian drugs, mainly dopamine agonists (6, 7).”
How close are we to individualized medicine for Parkinson’s disease?
Kim, H. J., & Jeon, B. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1182021 · Cited by 24
Impulse control disorder in Parkinson’s disease is associated with abnormal frontal value signalling
Tichelaar, J. G., Sayalı, C., Helmich, R. C. G., & Cools, R. (2023) · Brain · doi:10.1093/brain/awad162 · Cited by 23
“In sum, dopaminergic medication-related deficits in ventral striatal RPE signalling might be most readily seen in clinically more advanced PD patients with ICDs, who exhibit not only reduced phasic firing capacity of cells projecting to the ventral striatum, but also reduced ability to rely on a prefrontal working mem…”
InfluentialSocial behavioral changes in MPTP-treated monkey model of Parkinson's disease
Durand, E., Petit, O., Tremblay, L., Zimmer, C., Sgambato, V., Chassain, C., Laurent, M. ̈., Pereira, B., Silberberg, C., & Durif, F. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00042 · Cited by 28
“ORIGINAL RESEARCH ARTICLE published: 26 February 2015 doi: 10.3389/fnbeh.2015.00042 Social behavioral changes in MPTP-treated monkey model of Parkinson’s disease”
BackgroundInfluential
Metadata
- Authors
- Weintraub, D., Siderowf, A. D., Potenza, M. N., Goveas, J., Morales, K. H., Duda, J. E., Moberg, P. J., & Stern, M. B.
- Affiliations
- University of Pennsylvania (US)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2006-07-01
- Volume
- 63
- Issue
- 7
- Pages
- 969
- ISSN
- 0003-9942 (ISSN-L)
- PMC
- PMC1761054
- OpenAlex
- W2035890213
- Cited by
- 662
- References
- 17
- Citations by year
- 2026: 14 · 2025: 13 · 2024: 12 · 2023: 16 · 2022: 18 · 2021: 18 · 2020: 36 · 2019: 38 · 2018: 23 · 2017: 32 · 2016: 40 · 2015: 26 · 2014: 40 · 2013: 45 · 2012: 40
- FWCI
- 30.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (K23MH067894)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Social Sciences › Psychology › Clinical Psychology › Gambling Behavior and Treatments
- Keywords
- Parkinson's disease, impulse control disorders, dopamine agonists, gambling addiction, compulsive buying, compulsive sexual behavior, psychiatric complications, adverse drug reactions, risk factors, dose-response relationship
- MeSH terms
- Pramipexole, Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Gambling, Humans, Disruptive, Impulse Control, and Conduct Disorders, Indoles, Male, Middle Aged, Parkinson Disease, Pergolide, Risk Factors, Sexual Behavior, Sexual Dysfunction, Physiological, Thiazoles, Logistic Models, Dopamine Agonists, Benzothiazoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
